Noteworthy Friday Option Activity: CC, IBM, LXEO

Unusual options activity was recorded in IBM and Lexeo Therapeutics (LXEO): IBM options saw 15,715 contracts traded (~1.6 million underlying shares), roughly 42.3% of IBM's one‑month average daily volume (3.7M shares), led by 932 contracts in the $312.50 call expiring Jan 16, 2026 (~93,200 underlying shares). LXEO had 6,208 contracts (~620,800 underlying shares), about 42% of its one‑month average daily volume (1.5M shares), with particularly heavy activity in the $11 call expiring Jan 16, 2026 (2,891 contracts, ~289,100 shares). These flows indicate concentrated call positioning in both names and may reflect short‑term directional bets or hedging ahead of catalysts.

Analysis

Market structure: Large concentrated long‑dated call flow (IBM: 15,715 contracts ≈1.6M shares = 42.3% of ADV; LXEO: 6,208 contracts ≈620.8k shares = 42% of ADV) likely forces dealer delta-hedging into the cash market, creating near‑term upward pressure and higher implied vol. Winners are directional call buyers and brokers/market‑makers capturing spreads; pure short sellers and liquidity providers face elevated gamma exposure and funding needs. Cross‑asset impact is modest: expect short‑term bid to equity risk premia and option skews to steepen, minimal direct FX/commodity moves absent macro news.

Risk assessment: Tail risks differ: LXEO carries binary biotech event risk (trial/FDA) that can collapse value >90% in days; IBM’s tail is corporate action (asset sales/M&A) or macro drawdown that can compress multiples 15–30%. Immediate (days) — spot moves from hedging; short (weeks–months) — IV re‑rating and position unwind; long (to Jan 16, 2026) — option expiry outcomes dominate. Hidden dependency: flow may be sell‑to‑open or structured (buying calls as part of collars/synthetics), so validate trade direction with block trade/Time & Sales before committing.

Trade implications: For IBM, prefer defined‑risk bullish exposure: establish a Jan‑16‑2026 312.50/350 call spread sized 0.5–1.5% of NAV or buy the 312.50 call and sell 30–60 day calls (calendar) to fund cost; trim on a 20–30% realized move. For LXEO, avoid large equity exposure — if speculative, limit to ≤0.25% NAV in Jan‑16‑2026 $11 calls or sell near‑term premium if no catalyst; size conservatively and use 50–70% premium stop. Rotate 2–4% from small‑cap biotech into large‑cap enterprise tech to reduce idiosyncratic binary risk.

Contrarian angles: Consensus treats call prints as pure directional bullish signals but often they’re structured/hedges; when >40% of ADV is in options, dealer hedging can create a squeeze that reverts on position unwind (histor parallels: short‑lived gamma squeezes in 2018–2021). The trade that looks obvious (buying one‑sided long calls) is vulnerable to volatility collapses once positions roll off — prefer spreads or funded calendars to capture skew and avoid naked exposure.

Key Decisions for Investors

• Establish a defined‑risk bullish position in IBM: buy the Jan 16 2026 312.50/350 call spread sized 0.5–1.5% of NAV, set a 25% realized‑gain take and a 40% max loss on premium; implement within 5 trading days to capture current elevated hedging flows.
• Do not open >0.25% NAV outright long equity in LXEO; if speculating, buy Jan 16 2026 $11 calls sized ≤0.25% NAV and exit if the premium declines 70% or the stock fails to move ≥30% within 6 months.
• Harvest elevated near‑term implied volatility in IBM by selling 30–60 day call spreads (funding long‑dated bullish exposure) sized to 0.5% NAV, but cap net short‑vol exposure and hedge with protective puts if spot gaps >8% intraday.